LEARN MORE FROM THE CLINICAL INVESTIGATORS

Select a presentation below to hear more about MAVYRET from clinical investigators, and discover why it may be appropriate to consider MAVYRET for your patients with chronic HCV infection.


MAVYRET FOR 8 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITHOUT CIRRHOSIS EXCLUDING LIVER OR KIDNEY TRANSPLANT RECIPIENTS

Playing video 1 of 3

MAVYRET FOR 8 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITHOUT CIRRHOSIS EXCLUDING LIVER OR KIDNEY TRANSPLANT RECIPIENTS

with Dr. Mitchell Shiffman and Dr. Fred Poordad

MAVYRET FOR 12 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)

with Dr. Marcelo Kugelmas and Dr. Paul Pockros

MAVYRET FOR CHRONIC HCV PATIENTS WITH SEVERE RENAL IMPAIRMENT

with Dr. Steve Flamm and Dr. Robert S. Brown